Findings

What do systematic reviews say?

1,733 questions · 1,794 findings · 326 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 243 · 13.5%GRADE not reported 96 · 5.4%Very low 597 · 33.3%Low 506 · 28.2%Moderate 303 · 16.9%High 49 · 2.7%

Intervention not reported

All‐cause mortality at 10 days‐ short‐term treatment · patients with acute myocardial infarction1

The intervention leads to lower all‐cause mortality at 10 days‐ short‐term treatment (high certainty).

1 finding from 1 review

Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute… 2009 · Cochrane Headline outcomes only
RR 0.91 [0.86, 0.97]
6 studies · 78178 participants
High

Intervention not reported

All‐cause mortality at 10 days ‐ short‐term treatment · acute myocardial infarction1

The intervention leads to lower all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).

1 finding from 1 review

Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute… 2009 · Cochrane Headline outcomes only
RR 0.93 [0.87, 0.98]
10 studies · 84311 participants
High

Intervention not reported

All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction1

The intervention showed no clear difference in all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).

1 finding from 1 review

Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute… 2009 · Cochrane Headline outcomes only
RR 0.96 [0.91, 1.02]
14 studies · 71457 participants
High

Intervention not reported

All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction or stroke1

It is very uncertain whether the intervention changes all‐cause mortality at 10 days ‐ short‐term treatment (very low certainty).

1 finding from 1 review

Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute… 2009 · Cochrane Headline outcomes only
RR 1.01 [0.73, 1.38]
15 studies · 1900 participants
Very low

Short‐course L‐AmB + FLU vs two weeks of L‐AmB + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Short‐course L‐AmB + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of L‐AmB + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.03 [0.47, 2.25]
1 study · 79 participants
Low

Valaciclovir (short‐term) vs placebo

Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis

Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 0.55 [0.23, 1.28]
1 study · 125 participants
Moderate

Valaciclovir (short‐term) vs placebo

Incidence of HSL during use of the preventative intervention (by culture) · participants with recurrent herpes labialis

Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 0.47 [0.21, 1.08]
1 study · 125 participants
Moderate

Valaciclovir (short‐term) vs placebo

Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis

Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 1.33 [0.71, 2.5]
1 study · 125 participants
Moderate

Valaciclovir (short‐term) vs placebo

Viral load (shedding) in saliva · participants with recurrent herpes labialis

Valaciclovir (short‐term) showed no clear difference in viral load (shedding) in saliva compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 0.16 [0.02, 1.26]
1 study · 120 participants
Moderate

Questionnaire design: short vs usual questionnaire

Retention [ · trial participants being followed up for data collection

The review found no eligible studies for this question.

1 finding from 1 review

Strategies to improve retention in randomised trials 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral aciclovir (short‐term) vs placebo

Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis

Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 1.08 [0.62, 1.87]
1 study · 237 participants
Moderate

Oral aciclovir (short‐term) vs placebo

Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis

Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 0.26 [0.13, 0.51]
2 studies · 177 participants
Low

Oral aciclovir (short‐term) vs placebo

Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ aciclovir 200 mg 5 times/day · participants with recurrent herpes labialis

Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 0.46 [0.2, 1.07]
1 study · 66 participants
Low

Oral aciclovir (short‐term) vs placebo

Incidence of herpes labialis during use of the preventative intervention (by culture) ‐ aciclovir 400 mg twice daily · participants with recurrent herpes labialis

Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 0.05 [0, 0.7]
1 study · 30 participants
Low

Oral aciclovir (short‐term) vs placebo

Adverse effects during use of the preventative intervention ‐ aciclovir 800 mg twice daily · participants with recurrent herpes labialis

Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 0.98 [0.7, 1.38]
1 study · 239 participants
Moderate

Oral aciclovir (short‐term) vs placebo

Adverse effects during use of the preventative intervention ‐ aciclovir 400 mg twice daily · participants with recurrent herpes labialis

Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (low certainty).

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
RR 2.3 [0.62, 8.58]
2 studies · 183 participants
Low

Short duration (3 to 4 days) vs long duration (7 to 14 days) IV therapy

Persistent bacteriuria · children with acute pyelonephritis

Short duration (3 to 4 days) showed no clear difference in persistent bacteriuria after treatment compared with long duration (7 to 14 days) IV therapy (low certainty).

1 finding from 1 review

Antibiotics for acute pyelonephritis in children 2014 · Cochrane Headline outcomes only
RR 0.78 [0.24, 2.55]
4 studies · 305 participants
Low

Short duration (3 to 4 days) vs long duration (7 to 14 days) IV therapy

Recurrent UTI within 6 months · children with acute pyelonephritis

Short duration (3 to 4 days) showed no clear difference in recurrent UTI within 6 months compared with long duration (7 to 14 days) IV therapy (moderate certainty).

1 finding from 1 review

Antibiotics for acute pyelonephritis in children 2014 · Cochrane Headline outcomes only
RR 0.97 [0.58, 1.62]
5 studies · 993 participants
Moderate

Short duration (3 to 4 days) vs long duration (7 to 14 days) IV therapy

Persistent renal damage at 3 to 6 months: all included children with acute pyelonephritis · children with acute pyelonephritis

Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: all included children with… compared with long duration (7 to 14 days) IV therapy (moderate certainty).

1 finding from 1 review

Antibiotics for acute pyelonephritis in children 2014 · Cochrane Headline outcomes only
RR 1.01 [0.8, 1.29]
4 studies · 726 participants
Moderate

Short duration (3 to 4 days) vs long duration (7 to 14 days) IV therapy

Persistent renal damage at 3 to 6 months: children with initial renal parenchymal damage on initial DMSA scan · children with acute pyelonephritis

Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: children with initial… compared with long duration (7 to 14 days) IV therapy (moderate certainty).

1 finding from 1 review

Antibiotics for acute pyelonephritis in children 2014 · Cochrane Headline outcomes only
RR 1.1 [0.84, 1.45]
3 studies · 315 participants
Moderate